Get the weekly note

Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

IGIB vs XBI: how they differ

IGIB and XBI hold 0% of their weight in the same names, and XBI returned more over the year.

iShares 5-10 Year Investment Grade Corporate Bond ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, IGIB and XBI hold 0% of their money in the same securities at the same weight.

Largest positions each one holds and the other does not
Only in IGIBOnly in XBI
BLK CSH FND TREASURY SL AGENCY 0.60%MODERNA INC 2.87%
ANHEUSER-BUSCH COMPANIES LLC 0.20%TWIST BIOSCIENCE CORP 1.81%
SPACE EXPLORATION TECHNOLOGIES COR 144A 0.19%HALOZYME THERAPEUTICS INC 1.47%
PFIZER INVESTMENT ENTERPRISES PTE 0.18%NATERA INC 1.46%
QTS FAYETTEVILLE I DC1-2 LLC 144A 0.15%KYMERA THERAPEUTICS INC 1.45%
JPMORGAN CHASE & CO MTN 0.13%TRAVERE THERAPEUTICS INC 1.40%
MORGAN STANLEY (FXD-FRN) MTN 0.12%ROIVANT SCIENCES LTD 1.39%
WELLS FARGO & COMPANY (FXD-FRN) MTN 0.12%ORUKA THERAPEUTICS INC 1.38%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.

IGIB and XBI on the fields both publish, as of Sep 13, 2026. Source: ETFIQ.
IGIB
iShares 5-10 Year Investment Grade Corporate Bond ETF
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sitsCore index fundCore index fund
IssueriSharesState Street
What it is5-10 Year Investment Grade Corporate BondSPDR S&P Biotech
Total return, 1 year−1.0%+64.0%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500−18.5 pts+46.5 pts
Expense ratio0.04%0.35%
Holdings2951154

IGIB in plain words

IGIB is a bond fund tracking the 5-10 Year Investment Grade Corporate Bond. Over the year to Sep 11, 2026 it returned −1.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.04% a year. It sat 3.3% below its high of Feb 27, 2026 on Sep 11, 2026.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, IGIB or XBI?
In the year to Sep 13, 2026, with distributions reinvested, IGIB returned −1.0% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, IGIB or XBI?
IGIB charges 0.04% a year and XBI charges 0.35%, so IGIB is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

IGIB against XBI, ETFIQ, data as of Sep 13, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, IGIB against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/igib-vs-xbi Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources